A plan matched to your diabetes type
If insulin, injections, and glucose swings are running your life, our Istanbul endocrinology team builds your plan around your exact diabetes type — pairing established care with the right investigational protocol, precise dosing, and full aftercare during your stay.
Conceptual biological visualization
Evidence status
Insulin and automated delivery technology remain foundational for type 1 diabetes, while type 2 care addresses glucose, weight, heart, and kidney risk. Lantidra has a narrow donor-islet indication for selected adults with recurrent severe hypoglycemia, and we confirm eligibility before anything else.
We work with manufactured insulin-producing islet protocols in advanced trials for severe type 1 diabetes, and physician-monitored IV MSC protocols for patients seeking supportive care in type 2 diabetes, matched to your case by our endocrinology team.
We won't tell you a generic MSC or exosome infusion permanently restores beta cells, eliminates medication, or prevents kidney, eye, nerve, and cardiovascular complications. We focus on what current cell therapy can responsibly deliver.
A direct answer
Our Istanbul program starts by identifying exactly what your case needs: intensive insulin and technology optimization for type 1 diabetes, metabolic and complication-risk management for type 2, and — where appropriate — access to the right cell-based protocol. The FDA-approved cellular product Lantidra uses deceased-donor pancreatic islets for a narrow group of adults with type 1 diabetes and recurrent severe hypoglycemia. Stem-cell-derived islets such as zimislecel and MSC infusions remain investigational, and our physicians match you to the pathway your case actually supports.
Start with the phenotype
Replacing insulin-producing cells in autoimmune type 1 diabetes is different from treating insulin resistance and progressive beta-cell dysfunction in type 2 diabetes, and our physicians match your protocol accordingly.
Every Istanbul evaluation starts alongside expert diabetes care — never in place of insulin, continuous monitoring, education, or medicines that reduce established complication risk.
Autoimmune destruction of beta cells causes insulin deficiency, so lifelong insulin remains required unless functioning islets are successfully transplanted.
Insulin resistance, beta-cell decline, weight, liver, kidney, heart, sleep, medicines, and lifestyle interact over time.
Impaired awareness and recurrent episodes despite expert care define the narrow population studied for islet replacement.
LADA, monogenic, pancreatic, medication-related, and gestational diabetes need diagnosis-specific care and cannot borrow evidence automatically.
Product and route matter
"Stem cell therapy for diabetes" covers several distinct protocols with different goals, delivery routes, and evidence bases. Our team matches you to the one your case supports.
Lantidra contains donor pancreatic islets infused into the liver portal vein for a narrow severe type 1 diabetes indication.
Evidence boundaryIt is not stem-cell-derived, donor supply is limited, and portal infusion plus long-term immunosuppression can cause serious harm.
Zimislecel is a manufactured, fully differentiated islet-cell product infused into the portal vein.
Evidence boundaryPromising small-study results still require immunosuppression, long follow-up, and confirmation in a larger trial.
Encapsulation and gene-edited approaches aim to protect replacement cells from immune attack.
Evidence boundaryCell survival, oxygen supply, immune escape, retrieval, tumor risk, and durable glucose control remain research problems.
Small trials examine whether stromal-cell signaling changes insulin need, HbA1c, or insulin sensitivity.
Evidence boundaryAn IV MSC is not an insulin-producing islet transplant and has no established durable effect on diabetes complications.
Indexed evidence ledger
We read every trial by diabetes type, comparator, product, route, and outcome — never grouped under one generic stem-cell label.
Measure what changes
A precise baseline lets us follow real glucose control and treatment burden, using continuous glucose data, medication accounting, and long follow-up rather than an isolated reading.
Document third-party-assisted events, awareness, CGM time in range, time below range, and glucose variability.
Track HbA1c with total daily insulin, other medicines, weight, nutrition, and activity.
Stimulated C-peptide and mixed-meal testing distinguish graft function from changes in injected insulin.
Portal thrombosis, bleeding, infection, kidney injury, malignancy, immune suppression, eye, foot, nerve, and cardiovascular outcomes.
Clinical review before travel
Send us your records and our endocrinology team confirms your diabetes type, current technology and education, severe-hypoglycemia risk, and organ status — so you know exactly what to expect before you travel.
Transparent planning
An outpatient MSC infusion, donor-islet transplantation, and stem-cell-derived islets are priced as distinct programs. Your quote names the exact product, route, hospital, medication, and follow-up requirements, plus airport and hotel support for your stay.
Our 2026 MSC program planning range starts from $7,000-$18,000, giving you a transparent baseline before your free evaluation confirms the exact protocol and price. This range does not cover donor-islet or stem-cell-derived islet transplantation.
Is this deceased-donor islets, stem-cell-derived islets, MSCs, exosomes, or another product?
Does the evidence match my diabetes type, severe-hypoglycemia history, route, dose, and endpoint?
What cost should I plan for, and how many days will I spend in Istanbul?
How will CGM, severe hypoglycemia, insulin dose, HbA1c, C-peptide, complications, and durability be tracked?
Primary reading
FAQ
Request Medical Evaluation
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.
